Member Info for Energyshares

The Market has just clicked we have a seasoned Chairman steering the company now.

Shaun Chilton was most recently Chief Executive Officer ("CEO") of the formerly London-listed Clinigen Group plc ("Clinigen"), a global pharmaceutical and pharmaceutical services platform business, which he led through a significant growth journey. During his tenure, the company expanded through both an organic and a buy-and-build strategy which included successfully completing several transformational acquisitions. The Company was eventually sold to Triton Partners for a total consideration of c.£1.3 billion in April 2022.

Alongside his role as the CEO of Clinigen, Shaun was Non-Executive Chairman of C7Health, a disruptive, venture capital-backed medical technology and services business which executed an acquisitive growth journey before successfully being acquired by a strategic buyer in 2022.

Shaun has held a number of senior and executive commercial positions over more than 30 years in companies in pharmaceutical and pharmaceutical services industries. These include at Pfizer, Sanofi, Wolters Kluwer Health and KnowledgePoint360 Group (now part of UDG Healthcare).

"In Shaun We Trust"

To get my dollars back…..

Https://www.fiercebiotech.com/biotech/lilly-signs-140m-upfront-partnership-radionectics-latest-radiopharma-play

Touk

The nurses are looking for you,it’s shepherds pie tonight followed by apple crumble back to the home you go…..

I think we should tell Merck about Avacta Pre/Cision 100% safer and 10 x more powerful than ADC’s.

https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-approve-merck-daiichis-guided-missile-cancer-drug-2024-06-27/

Last time Avacta SP was in the low forties Jupiter had raised their short to 1.03% then we had AACR poster and that chased them away,over the next six months they withdrew their short down to 0.3%.SP recovered to £1.40ish.

Now GSA at 0.7% they were taking advantage of the Three Stooges running the show.

I expect them to start exiting now with Avacta now being managed serious and not just a life style company for certain individuals,with expected news around the corner SP back over a £1 by late summer I hope.

It isn’t just the Pre/Cision Platform BP are watching they have one eye AVA6000 ODD approval.

Under a little-known FDA policy, ODD, once granted, never expires and it isn't limited to the drug product that was originally designated. Instead, it can be used over and over again to transfer ODD status to new drugs in the original sponsor's product line, as long as the active moiety remains the same. So any variation of that drug does not have to request for ODD and will get the seven years exclusivity on this new drug variant without even proving that it is superior to the original drug. The idea for allowing the variant is that FDA is approving the active moiety rather than the product formulation. This makes it more attractive for pharma and biotech companies to work on drugs or biologics for rare diseases where they can get exclusivity extended through building these smart variants. This can help companies make money over a period of time with no competition and at the same time help the patients with these rare diseases.  

Agree Bella

First time I have heard Avacta going for AA

today, She mentioned the cost of P2 and P3 are only for BP backing.

Not everyone gets FDA don’t grant AA the sponsor company has to ask for it.

FDA will then pass if data is good and P2 & P3 in place.

My take they are running this now with a BP backer.

RNS

23 May 2024

Dosing of the second cohort in Arm 2 has now commenced, with three patients successfully dosed.

RNS Today

Arm 2 of the Phase 1 trial for AVA6000, a peptide drug conjugate form of doxorubicin chemotherapy, has successfully completed its second cohort without dose limiting toxicities observed. Patients are now being dosed in the third cohort.

So four and a half weeks for 2nd 2WD cohort so if 3rd and 4th go to same time lines

Last week in August 2WD will be finished unless they go for another dose.

But with all the 100% on time comments today they look in a rush to get to 1b expansion cohorts.

Derby watch the boosting very soon

Imagine winning the Euro Lottery Jackpot,but hiding your ticket away for two and half years and Not telling anyone and being a smug twat with your best two mates.

Then finding out you have missed the deadline to cash it in.

Then someone else has just won the same amount with the same numbers but cashed it in before the deadline.

Sounds familiar…

They again100% on track and kept repeating this….

My opinion they have a BP 100% working with them.

AA approval 2025 ……

We are coming up to 3 years in six weeks time, for the AVA6000 trial start date.

Avacta have made tremendous and very impressive strides in this trial

multiple RNS’s and not one negative RNS has been put out, nothing but positive news.

In fact the trial has been changed because of the outstanding results of each cohort.

But the SP stands at a third of the value it was as of 11/08/21.

This just shows you this AIM market and the government are not fit for purpose for UK tech and Bio firms.

I hope BP value Avacta at its true potential and not what these clowns on AIM value it at.

Now the Three Stooges have gone the future looks bright.

EF,AS,TG

Having the Holy Grail and not Boosting it to the world has cost these Three Stooges their job,reputations and probably a knighthood for AS.

Curly,Larry and Mo have learnt the hard way about the dark side of AIM manipulators.

This could be the date for Rockets nearly 2 years since last Research day….

“we look forward to our Research and Development Spotlight Science Day in London in the fourth quarter of 2024 where we’ll be providing more detail on the future of the pre|CISION™ platform.”

Cancer tumours on the 3 rd dose of 2WD trial…

https://m.youtube.com/watch?v=qCCzFnXKYjo&pp=ygUcYmFzaGluZyBmcm9ncyBhcmNhZGUgbWFjaGluZQ%3D%3D

Darlene M Deptula-hicks has CFO experience so will be watching sticky fingers Gardiner before he f.u.c.k s off

Darlene M Deptula-hicks is the SVP, CFO of Pieris Pharmaceuticals Inc and owns about 63 shares of Pieris Pharmaceuticals Inc stock worth over $541. Darlene M Deptula-hicks is also the SVP & CFO of T2 Biosystems Inc and owns about 40 shares of T2 Biosystems Inc stock worth over $268.

What are they seeing in 2W study to assemble this Scientific Advisory Board is this unprecedented in a phase 1 trial ??

Coris operations in Belgium has enabled the Group to close the Wetherby laboratory facilities, resulting in operational cost savings.

I’d love an offer of £1.26 just to get my money back then BP can fight it out for my profit….😂

What’s the brewery called

Forster’s Lager “Good day”